Intervacc is trading 19.73% down at €0.05, with no clear company-specific explanation identified. - A November 3 announcement reported only three confirmed infections among horses completing primary vaccination after 100,000 Strangvac doses were sold; the update was positive and is not an evident explanation for the decline. - Biotech was up 2.13%, so the available sector context does not explain the fall.